Differential Protein-Coding Gene Expression Profile in Patients with Prostate Cancer
Authors:
- Lorena Albarracín-NavasLALorena Albarracín-Navas
- Maylin Almonte-BecerrilMAMaylin Almonte-Becerril
- Enmanuel GuerreroEGEnmanuel Guerrero
- Josue RivadeneiraJRJosue Rivadeneira
- Marcelino Telechea-FernándezMTMarcelino Telechea-Fernández
- Elizabeth GuzmánEGElizabeth Guzmán
- Fanny CalderónFCFanny Calderón
- María José Hernández-LealMHMaría José Hernández-Leal
- Tamara OtzenTOTamara Otzen
- Carlos ManterolaCMCarlos Manterola
- Galo DuqueGDGalo Duque
- Ángela L. Riffo-CamposÁRÁngela L. Riffo-Campos
Open Access
- 1 November 2024
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 12 (11) , 2509
Abstract
Background: Prostate cancer is the second most common neoplasm in men, with projections estimating over one million new cases by 2045. Differentially expressed genes can significantly enhance the diagnosis, treatment, monitoring, and prognosis of this disease. Purpose: to systematically review and analyze validated differentially expressed mRNAs in prostate cancer patients to propose a robust molecular profile for clinical diagnostics. Methods: A systematic review was conducted following PRISMA guidelines, searching literature databases for mRNAs with validated differential expression in adult prostate cancer patients. Identified mRNAs were analyzed using STRING, Cytoscape, and DrugBank to explore protein–protein interactions and potential drug targets. Results: A total of 5003 participants from Europe, Asia, America, and Oceania were included, and 144 mRNAs (p < 0.05) were reported across 75 primary articles, predominantly validated using RT-qPCR with tissue samples. Among these, at least 36 mRNAs were identified as targets for cancer-related drugs. Enrichment analysis revealed the top pathways were associated with cancer, including specific prostate cancer terms. Key nodes emerged as hubs in the protein–protein interaction network. Conclusion: Based on our comprehensive in silico analysis of validated differentially expressed mRNAs, we propose a molecular profile of twenty-five mRNAs with significant potential for clinical diagnosis of prostate cancer. These findings offer a valuable foundation for developing precision oncology strategies to improve patient outcomes.Keywords
Funding Information
- Universidad de La Frontera (DIUFRO DI22-0014, NCS2021_013, ANID FONDAP 152220002)
- ANID–Millennium Science Initiative Program (DIUFRO DI22-0014, NCS2021_013, ANID FONDAP 152220002)
- CECAN (DIUFRO DI22-0014, NCS2021_013, ANID FONDAP 152220002)
This publication has 62 references indexed in Scilit:
- Human Saliva as a Diagnostic Specimen for Early Detection of Inflammatory Biomarkers by Real-Time RT-PCRInflammation, 2021
- Differential expression of protein disulfide-isomerase A3 isoforms, PDIA3 and PDIA3N, in human prostate cancer cell lines representing different stages of prostate cancerMolecular Biology Reports, 2021
- Androgen Receptor Dependence2019
- RNA‐based markers in biopsy cores with atypical small acinar proliferation: Predictive effect of T2E fusion positivity and MMP‐2 upregulation for a subsequent prostate cancer diagnosisThe Prostate, 2018
- The Diagnosis and Treatment of Prostate CancerJAMA, 2017
- Use of two gene panels for prostate cancer diagnosis and patient risk stratificationTumor Biology, 2016
- Perfil de expresión génica en el cáncer de próstata: identificación de marcadores candidatos para el diagnóstico no invasivoActas Urológicas Españolas, 2014
- Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesionsCancer Detection Prevention, 2006
- Loss of stearoyl‐CoA desaturase expression is a frequent event in prostate carcinomaInternational Journal of Cancer, 2004
- α-Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate CancerJAMA, 2002